The flu season has been good for the $6.5 billion-a-year cough-and-cold market, writes Jack Neff. Reckitt Benckiser, which entered the U.S. by buying Mucinex, Delsym and Cepacol, has seen sales increase 22% over last year in the four weeks ending Dec. 22. Havas Worldwide has been handling the advertising with symptom- and geo-targeting, and the brand has an overnight-shipping deal with Drugstore.com. Johnson & Johnson has rebounded somewhat from a Tylenol recall by restarting production and relaunching Children's Motrin via agency JWT. J&J cough-cold sales were up 38% in the same period.